Braat S, Kooy RF. Insights into GABAAergic system deficits in fragile X syndrome lead to clinical trials. Neuropharmacology. 2015 Jan;88:48-54. PMID: 25016041.
From the abstract: "An increasing number of studies implicate the GABAAergic system in the
pathophysiology of the fragile X syndrome, a frequent cause of
intellectual disability and autism. Animal models have proven invaluable ... Aberrations compatible
with those described in the mouse model were detected in dfmr1 deficient
Drosophila melanogaster, a validated fly model for the fragile X
syndrome. Treatment with drugs that ameliorate the GABAAergic deficiency
in both animal models have demonstrated that the GABAA receptor is a
promising target for the treatment of fragile X patients. Based on these
preclinical studies, clinical trials in patients have been initiated."